NEW YORK (GenomeWeb News) — Fluidigm said today that it expects total revenue for the fourth quarter of 2013 to be approximately $21 million, beating consensus analyst estimates of $19.5 million and representing a 34 percent spike compared to Q4 2012 revenues of $15.7 million.

Based on preliminary, unaudited financial data, Fluidigm said that it expected Q4 instrument revenue to be approximately $12 million and consumables revenue to be approximately $8.5 million compared to $9.6 million and $5.8 million, respectively, in the same quarter last year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.